Abstract
S460 Efficacy and Safety of IRL201104, a Novel Peptide Immunomodulator, in a Phase 2a, Double-Blind, Placebo-Controlled Multi-Center Study in Patients With Active Eosinophilic Esophagitis
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
